Flu Vaccine Evolution: A Tri-Lineage Future and the Watch on Avian Threats
The World Health Organization (WHO) has announced its recommendations for influenza vaccine composition for the 2026-2027 Northern Hemisphere influenza season. A significant shift is underway, with a continued move towards tri-valent vaccines and a first-time omission of recommendations for tetravalent formulations. This decision reflects the apparent disappearance of the influenza B/Yamagata lineage, a development with major implications for global flu prevention strategies.
The Yamagata Lineage: A Silent Exit?
Since March 2020, confirmed circulation of the influenza B/Yamagata lineage has not been detected globally. This prolonged absence has led the WHO to conclude that including a Yamagata component in flu vaccines is no longer necessary. For the first time, the organization is not issuing compositional recommendations for tetravalent vaccines, leaving the decision to individual countries.
This isn’t a hasty decision. The WHO’s recommendations are based on extensive surveillance data, antigenic and genetic characterization of circulating viruses, and analysis of vaccine effectiveness. The Global Influenza Surveillance and Response System (GISRS), comprised of 168 reference centers in 138 countries, plays a crucial role in this ongoing monitoring process.
Focus on Victoria and Evolving A Strains
The recommended tri-valent vaccines for the 2026-2027 season will target:
- An A/Missouri/11/2025 (H1N1)pdm09-like virus
- An A/Darwin/1454/2025 (H3N2)-like virus
- A B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus
The emergence of a notably different A(H3N2) variant (subclade K) in August 2025, which spread rapidly worldwide, contributed to an earlier and more intense flu season in many regions. This highlights the constant need for vaccine updates to match circulating strains.
The Rise of Zoonotic Influenza and Pandemic Preparedness
Beyond seasonal influenza, the WHO is increasingly focused on zoonotic influenza viruses – those that jump from animals to humans. As of September 23, 2025, 25 human infections with zoonotic influenza viruses had been reported from six countries, primarily through exposure to infected animals. While human-to-human transmission hasn’t been observed, these viruses pose a pandemic threat.
The WHO is actively evaluating these zoonotic viruses and identifying potential vaccine candidates (VVCs) that could be rapidly deployed in the event of a pandemic. Experts recently recommended the development of a latest VVC for an A(H9N2) virus.
What Does This Indicate for the Future of Flu Vaccines?
The shift towards tri-valent vaccines represents a significant streamlining of influenza prevention efforts. By focusing on the currently circulating strains, resources can be allocated more efficiently. Yet, continuous surveillance remains paramount. The possibility, however remote, of the Yamagata lineage re-emerging necessitates ongoing monitoring.
The increased attention to zoonotic influenza underscores the interconnectedness of human and animal health. Proactive surveillance and vaccine development are essential to mitigate the risk of future pandemics.
FAQ: Influenza Vaccine Composition 2026-2027
Q: Why is the Yamagata lineage being dropped from some flu vaccines?
A: The influenza B/Yamagata lineage hasn’t been detected in confirmed cases since March 2020, making its inclusion in vaccines unnecessary.
Q: What are “like viruses”?
A: “Like viruses” are strains that are antigenically similar to the recommended vaccine viruses, allowing manufacturers flexibility in selecting strains for vaccine production.
Q: Is the H3N2 subclade K a major concern?
A: Yes, the H3N2 subclade K caused an earlier and more intense flu season in 2025, highlighting the need for vaccine updates.
Q: What is the WHO doing about avian influenza?
A: The WHO is monitoring zoonotic influenza viruses and developing potential vaccine candidates to prepare for potential pandemics.
Did you know? The WHO’s recommendations are used by national regulatory agencies and pharmaceutical companies worldwide to develop and license influenza vaccines.
Pro Tip: Staying informed about the latest flu vaccine recommendations and getting vaccinated annually is the best way to protect yourself and your community.
Explore more about influenza and vaccine development on the WHO website.
Related reading